


RealRate

PHARMACEUTICAL 2022



Edgewise Therapeutics Inc. Rank 74 of 475





PHARMACEUTICAL 2022





Edgewise Therapeutics Inc. Rank 74 of 475

The relative strengths and weaknesses of Edgewise Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edgewise Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 220% points. The greatest weakness of Edgewise Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 362% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	283,773
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,521
Liabilities, Non-Current	329
Other Assets	548
Other Compr. Net Income	-514
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	912
Research and Development	32,189
Revenues	402
Selling, General and Administrative Expense	11,026

Output Variable	Value in 1000 USD
Assets	285,233
Liabilities	10,850
Expenses	43,215
Stockholders Equity	274,383
Net Income	-42,813
Comprehensive Net Income	-43,070
Economic Capital Ratio	86%